Lumiradx announces commercial shipment of its point of care nt-probnp test in europe, supporting heart health checks in uk

London, jan. 31, 2023 (globe newswire) -- lumiradx limited (nasdaq: lmdx), a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care nt-probnp test to aid in the diagnosis of chf across europe.
LMDX Ratings Summary
LMDX Quant Ranking